Alternatively, compounds that potentiate sodium channel function could prove beneficial for DS, where 80% of patients carry loss-of-function (LOF) mutations in the SCN1A gene (Depienne et al., 2009; Richards et al., 2018). This evidence concerns the gene SCN1A and Dravet syndrome.